Sona Nanotech Inc
- Country
- 🇨🇦Canada
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 10
- Market Cap
- -
- Website
- https://www.sonanano.com
- Introduction
Sona Nanotech Inc is engaged in researching and developing gold nanorod products. It makes products for diagnostic tests and medical treatment applications. The company's product includes Gemini and Saliva tests.
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic Melanoma
- Conditions
- Cutaneous Metastatic Melanoma
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Sona Nanotech Inc
- Target Recruit Count
- 10
- Registration Number
- NCT06894407
Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma
- Conditions
- Cutaneous Metastatic Melanoma
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Sona Nanotech Inc
- Target Recruit Count
- 10
- Registration Number
- NCT06870994
Clinical Evaluation of the SONA Saliva C-19 Rapid Self-Test for the Detection of COVID-19
- Conditions
- Sars-CoV-2 Infection
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Sona Nanotech Inc
- Target Recruit Count
- 500
- Registration Number
- NCT05256589
- Locations
- 🇨🇦
COVID-19 Assessment centre @bayers lake, Halifax, Nova Scotia, Canada
Performance Study of SONA Saliva C-19 Rapid Test
- Conditions
- Sars-CoV-2 InfectionCorona Virus InfectionCovid19
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Sona Nanotech Inc
- Target Recruit Count
- 20
- Registration Number
- NCT04877002
- Locations
- 🇨🇦
Humber River Hospital, Toronto, Ontario, Canada
News
Sona Nanotech's Gold Nanorods Pass Critical Endotoxin Testing Ahead of First Human Cancer Trial
Sona Nanotech has successfully completed bacterial endotoxin testing on its biocompatible gold nanorods, with all samples showing endotoxin levels below detection limits.
BioVaxys and Sona Nanotech Partner to Develop Novel Cancer Immunotherapy Combining DPX Platform with Gold Nanorod Technology
BioVaxys Technology and Sona Nanotech have formed a research collaboration to develop innovative cancer therapeutics by combining BioVaxys' DPX immune educating platform with Sona's targeted hyperthermia therapy using gold nanorods.
Novel Gold Nanorod Therapy Shows Promise for 'Cold' Tumor Treatment, To Be Presented at Canadian Melanoma Conference
Sona Nanotech's innovative Targeted Hyperthermia therapy, utilizing biocompatible gold nanorods, demonstrates effectiveness in treating immunogenically 'cold' tumors through controlled heat delivery.